F2RL1 and Hepatic fibrosis: Increasing evidence suggests that PAR-2 plays an important role in HSCs activation and liver fibrosis, and PAR-2 antagonists may represent a novel therapeutic approach in preventing fibrosis in patients with chronic liver disease4, 7–9, 15.